Cancer Gene Therapy Market size to exceed $4.3bn by 2024 - PowerPoint PPT Presentation

View by Category
About This Presentation

Cancer Gene Therapy Market size to exceed $4.3bn by 2024


Cancer Gene Therapy Market Size By Type, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024 – PowerPoint PPT presentation

Number of Views:34


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Cancer Gene Therapy Market size to exceed $4.3bn by 2024

Cancer Gene Therapy Market size to exceed 4.3bn
by 2024, with 20.7 CAGR estimation from 2016 to
2024 Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
Key Insights from Cancer Gene Therapy Market
  • U.S. cancer gene therapy market share accounted
    for over 95 regional revenue in 2015, with
    market size of USD 235 million and a forecast to
    grow at 20.9 CAGR.
  • UK was over USD 92.0 million in 2015, and will
    grow at 20.8 CAGR owing to increasing incidence
    of cancer and adoption of advanced treatment
  • China market size was valued at USD 99.6 million
    in 2015 and growth expectations of 21 CAGR over
    the forecast years.

  • Key players include SiBiono, Altor Bioscience
    Corporation, Shanghai Sunway Biotech company
    limited, Amgen, BioCancell, OncoGeneX, Aduro
    Biotech, GlobeImmune, Inc., New Link Genetics.,
    ZioPharm Oncology, MolMed, GENELUX, Gradalis,
  • The industry is highly fragmented and is
    dominated by several small biotech firms
    collectively accounting for over 80 of cancer
    gene therapy market pipeline. Major growth
    strategies adopted by these small firms include,
    technology transfer, licensing and
    commercialization deals, strategic collaborations
    and mergers and acquisitions to retain their
    industry position.

U.S. Cancer Gene Therapy Market size, by type,
2012 - 2024 (USD Million)


Browse Full Market Research Report On Cancer
Gene Therapy Market _at_ http//
Request for a Sample of this Research
Report _at_ https//
/detail/763 https//
360 Analysis
  • Therapy Analysis
  • Transfer cancer gene therapy market share was
    over 46 of global revenue in 2015, and is see
    growth of 20.9 throughout the forecast period.
    Adenoviral vector is most commonly used oncology
    application due to its competent nuclear
    mechanism and low pathogenicity. Adenoviral
    vectors are used in gene replacement approaches,
    suicide gene, gene-based immunotherapy, and
    syndicate gene with chemotherapy over 20 growth
    is forecast for this segment.
  • Regional Analysis
  • China cancer gene therapy market size is
    estimated to account for 35.4 of APAC revenue in
    2015, being the first country to commercialize
    the gene therapy cancer drugs. Gendicine obtained
    license from the SFDA for its recombinant Ad-p53
    gene therapy for head and neck squamous cell
    carcinoma. The increasing healthcare expenditure
    and robust RD facilities will enable industry
  • Competitive Market Share
  • Major players include  SiBiono., Shanghai Sunway
    Biotech company limited, Altor Bioscience
    Corporation, Amgen, BioCancell, Aduro Biotech,
    OncoGeneX, GlobeImmune, Inc., New Link Genetics.,
    MolMed S.p.A, ZioPharm Oncology, Gradalis,
    GENELUX, MultiVir.

Stay In Touch Website Soci
al Media